Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys 93,124 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 93,124 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were purchased at an average price of $17.54 per share, for a total transaction of $1,633,394.96. Following the completion of the acquisition, the insider now owns 12,074,275 shares of the company’s stock, valued at $211,782,783.50. The trade was a 0.78 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The shares were purchased at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The stock was bought at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was bought at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The stock was bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The stock was bought at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was acquired at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

Shares of STAA stock traded down $0.33 during trading hours on Thursday, hitting $17.92. 1,073,972 shares of the company were exchanged, compared to its average volume of 760,650. The firm has a market cap of $883.90 million, a P/E ratio of -43.71 and a beta of 0.66. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68. The company has a 50 day simple moving average of $19.97 and a two-hundred day simple moving average of $25.81.

Institutional Trading of STAAR Surgical

Large investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of STAAR Surgical during the 3rd quarter worth approximately $50,000. Quest Partners LLC bought a new position in shares of STAAR Surgical in the 3rd quarter worth $128,000. KLP Kapitalforvaltning AS bought a new position in shares of STAAR Surgical in the 4th quarter worth $180,000. Larson Financial Group LLC lifted its holdings in shares of STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after purchasing an additional 2,135 shares in the last quarter. Finally, Bridgefront Capital LLC lifted its holdings in shares of STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Stephens reaffirmed an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday. Canaccord Genuity Group dropped their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Jefferies Financial Group cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Finally, StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and an average price target of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.